Tech Mahindra Launches FiDaaS Solution Powered by Alveo to Address Financial Services’ Data Management Challenges
8.12.2021 09:44:00 EET | Business Wire | Press release
Tech Mahindra, a leading provider of digital transformation, consulting and business reengineering services, has selected Alveo, a leader in market data integration and analytics solutions for financial services, as the technology underpinning an integrated Financial Data as a Service Proposition to the Financial Services Industry.
The FiDaaS Solution provides a cloud-based, Centralized Market Data Platform which offers a comprehensive solution for pricing and reference data management and covers end to end Financial Data Management requirements. The solution covers Data Acquisition, Data Mastering, Data Quality Management, Data Discovery and Distribution.
The Tech Mahindra FiDaaS solution will be offered in partnership with Alveo, as the underlying technology, and will include:
- Reference Data Management Solutions for security set-up and post-trade processing as well as ESG data management
- Market Data Management Solutions for Portfolio valuation (e.g. NAV and IPV), Sensitivity measures, and Index and ETF Data Management
- Risk Data Management Solutions for risk factor data, back-testing, scenario analysis and stress testing
Financial Services firms need to handle increasing volumes, additional data sources and need to provide their business users and applications with quality checked and validated information for risk, valuation, operations, trade enablement, finance, and advanced analytics. In this regard, FiDaaS will improve operational efficiencies by streamlining the management and control and tracking of data to enhance governance and verification for regulatory reporting.
The Tech Mahindra “Powered by Alveo” partnership brings together two global specialists with the complementary capabilities needed to realize transformative outcomes with a vision and a commitment to co-innovate.
Vivek Agarwal, President – BFSI, HLS and Corporate Development, Tech Mahindra, said, “Value and reliability of instrument data that financial institutions have access to, has far reaching impact on their reputation and regulatory scrutiny. Inaccuracy and unavailability of this data increases risk and causes significant financial losses. A sophisticated data management platform is central to ensuring data quality, data lineage, data cost monitoring, automation and self-services for global enterprises. Our partnership with Alveo is a step in this direction. Through this collaboration, we aim to help financial services customers to achieve the objectives of better-quality data at right cost while also getting the best analytical features from the historical financial data repository. We are looking forward to work with Alveo and driving the financial services customers towards Data -as-a-Service model.”
As part of the NXT.NOW TM framework, Tech Mahindra aims to enhance human centric experiences for businesses. This means focusing on investing in emerging technologies and solutions that enable digital transformation to better meet the evolving needs of its customers through our DigitALL framework.
Mark Hepsworth, CEO, Alveo, said, “Our partnership with Tech Mahindra is another step forward in rolling out Data-as-a-Service offerings to the financial services industry. The speed of onboarding, flexibility in consumption and lower cost of change whilst providing users a clear set of controls, dashboards and configuration options have made Data-as-a-Service the model of choice when it comes to sourcing data management capabilities. We are delighted to welcome Tech Mahindra to the ‘Powered by Alveo’ program and look forward to working closely together.”
Connect with us on www.techmahindra.com
Our Social Media Channels
Facebook: https://www.facebook.com/TechMahindra
Twitter: https://twitter.com/Tech_Mahindra
LinkedIn: https://www.linkedin.com/company/tech-mahindra/
YouTube: https://www.youtube.com/user/techmahindra09
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207006253/en/
Contact information
For more information on Tech Mahindra, please contact:
Abhilasha Gupta, Global Corporate Communications and Public Affairs
Email: Abhilasha.Gupta@TechMahindra.com, media.relations@techmahindra.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release
Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio
The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 15:00:00 EEST | Press release
The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i
Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 15:00:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are: Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of Michael Kors’ strongest performance periods. Titan of Europe: Ash Cummings, Ecommerce Fraud Prevention Manager, Gymshark A
CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release
CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit
Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release
Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom